4 Analysts Have This to Say About Deciphera Pharmaceuticals
Within the last quarter, Deciphera Pharmaceuticals (NASDAQ:DCPH) has observed the following analyst ratings:
Cowen & Co. Initiates Coverage On Deciphera Pharmaceuticals with Outperform Rating, Announces Price Target of $25
Cowen & Co. analyst Tyler Van Buren initiates coverage on Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform rating and announces Price Target of $25.
Deciphera’s Cancer Drug Tops Pfizer’s Sutent On Safety Front In Gastrointestinal Cancer
The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced…
HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $20
HC Wainwright & Co. analyst Andrew Fein maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and raises the price target from $15 to $20.
JMP Securities Upgrades Deciphera Pharmaceuticals to Market Outperform, Announces $23 Price Target
JMP Securities analyst Reni Benjamin upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Market Perform to Market Outperform and announces $23 price target.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million.